Novartis, Sandoz In Tangle With Trade Channels Over Direct Drug Sales In India
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian trade organization alleges the companies violated agreements by selling high-value drugs directly to patients, triggering a boycott of their products.
You may also be interested in...
Novartis Wants Tighter Grip Over Its Indian Ops; Announces Open Offer To Up Stake To 90%
MUMBAI - Swiss-headquartered Novartis announced a tender offer to buy an additional stake of up to 39 percent in its majority-owned Indian subsidiary Novartis India. The Swiss drug maker, which markets popular pain killer Voveran (diclofenac) in India among several other products, would raise its stake in the subsidiary to nearly 90 percent if the open offer for the shares passes successfully
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.